2seventy Bio price target lowered to $6 from $7 at Morgan Stanley
PremiumThe Fly2seventy Bio price target lowered to $6 from $7 at Morgan Stanley
3M ago
2seventy bio Strikes Strategic Gene Therapy Deal with Novo Nordisk
Premium
Company Announcements
2seventy bio Strikes Strategic Gene Therapy Deal with Novo Nordisk
4M ago
2seventy Bio announces sale of Hemophilia A candidate for up to $40M
Premium
The Fly
2seventy Bio announces sale of Hemophilia A candidate for up to $40M
4M ago
2seventy Bio reports Q1 EPS ($1.01), consensus( 81c)
PremiumThe Fly2seventy Bio reports Q1 EPS ($1.01), consensus( 81c)
6M ago
2seventy Bio price target raised to $12 from $9 at Citi
Premium
The Fly
2seventy Bio price target raised to $12 from $9 at Citi
7M ago
2seventy bio’s Abecma Wins FDA Approval for Multiple Myeloma
Premium
Company Announcements
2seventy bio’s Abecma Wins FDA Approval for Multiple Myeloma
7M ago
2seventy bio CSO Exits, Abecma Advances with FDA Committee
PremiumCompany Announcements2seventy bio CSO Exits, Abecma Advances with FDA Committee
8M ago
2seventy bio trading resumes
Premium
The Fly
2seventy bio trading resumes
8M ago
Bristol Myers, 2seventy Bio: FDA’s ODAC votes in favor of Abecma
Premium
The Fly
Bristol Myers, 2seventy Bio: FDA’s ODAC votes in favor of Abecma
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100